

Adolescent and Young Adult Committee

Wednesday, October 11, 2023 | 4:00 PM - 6:00 PM CT

A. Welcome and Introductions

Becky Johnson, MD

B. AYA Community Advocate Booth at this meeting

Lauren Fryzel

C. Updates and Trials in Development

- **S1826** A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age \geq 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Alex Herrera, MD (virtual)
- **ACCL1931** A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in AYAs with ALL
Etan Orgel, MD (virtual)
- **S2307** A Phase 1B Study Assessing the Safety and Activity of SNDX-5613 (revumenib) in Combination with Age-Modified Chemotherapy in Newly Diagnosed patients with KMT2Ar acute lymphoblastic leukemia (ALL) or acute leukemia with ambiguous lineage (ALAL)
Ibrahim Aldoss, MD (virtual)
- **ALTE2131** An NCTN-wide randomized clinical trial of gonadotropin-releasing hormone analogs (GnRH α) for protection of ovarian reserve in AYAs with cancer
Halle Moore, MD
- **AHOD2131** A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classical Hodgkin Lymphoma
Boyu Hu, MD
- **ACCL21C2** AYA COVID vaccine study
Becky Johnson, MD
- **EAQ202** Improving AYA Self-Reported Data
Becky Johnson, MD
- **AYA Sexuality Study**
Adam Duvall, MD, PhD
- **NCORP Pilot Grant "TALK TO ME: Tailored AYA Trial Messaging"**
Allison Rosen, MS; Melissa Beauchemin, PhD

D. AYA-Relevant Projects of Breast Committee

Erin Roesch, MD (New AYA Committee Liaison to Breast Committee)

E. Guest Speaker: Global Burden of AYA Cancer

Elysia Alvarez, MD (UC Davis)

F. Q&A and discussion

Becky Johnson, MD and Lucia Nappi, MD, PhD